QuidelOrtho (QDEL)
(Delayed Data from NSDQ)
$40.82 USD
+0.42 (1.04%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $40.82 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
B Value D Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
QDEL 40.82 +0.42(1.04%)
Will QDEL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for QDEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QDEL
QuidelOrtho's (QDEL) New Test to Offer Enhanced Opioid Testing
QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing
QDEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis
QuidelOrtho (QDEL) Q4 Earnings and Sales Miss, Margins Fall
QuidelOrtho (QDEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for QDEL
First Week of QDEL December 20th Options Trading
What's Driving Inspire Medical Systems Inc's Surprising 24% Stock Rally?
QuidelOrtho To Report First Quarter 2024 Financial Results
Class Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) Seeking Recovery for Investors – Contact Levi & Korsinsky LLP
Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives